Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443728 | 0.83 | CA1 (0.59) | CA1CA2CA7CA9CASP1 | |
| SCHEMBL7618020 | 0.80 | TDP1 (0.41) | CA1CA2CA7CA9CASP1 | |
| SCHEMBL19341237 | 0.80 | CA1 (0.41) | CA1CA2CA7CA9CASP1 | |
| SCHEMBL7086367 | 0.77 | CA1 (0.54) | CA1CA2CA7CA9CA4 | |
| SCHEMBL18604307 | 0.74 | CA1 (0.52) | CA1CA2CA7CA9TDP1 | |
| Malic Acid SCHEMBL3809544 | 0.73 | SMN1; SMN2 (0.60) | CA1CA2CA7CASP1TDP1 | |
| SCHEMBL10633727 | 0.73 | CA1 (0.50) | CA1CA2CA7CA9CA4 | |
| SCHEMBL811520 | 0.73 | CA1 (0.50) | CA1CA2CA7CA9CA4 | |
| SCHEMBL11508517 | 0.72 | CA1 (0.50) | CA1CA2CA7CA9TDP1 | |
| Bicarbonate SCHEMBL1206563 | 0.71 | CA1 (0.41) | CA1CA2CA7CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433150-B2 | Anthracycline analogues bearing latent alkylating substituents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-13 | — | — | US | disclosed |
| US-20010053845-A1 | Anthracycline analogues bearing latent alkylating substituents | BOARD OF REGENTS | 2001-12-20 | — | — | US | disclosed |
| US-6284737-B1 | ANTICARCER AGENTS | PRO-NEURON, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0555358-B1 | ANTHRACYCLINE ANALOGUES BEARING LATENT ALKYLATING SUBSTITUENTS | UNIV TEXAS (US) | 1994-08-10 | — | — | EP | disclosed |
| US-5196522-A | Antitumor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053845-A1 | Anthracycline analogues bearing latent alkylating substituents | BCR, MCL1, NCL | CA1 826/4885CA2 2396/4885CA7 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.